NCT07107659招募中1 期
Safety and Efficacy of ONTO1 in Lupus
Hospital for Special Surgery, New York1 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2026年9月4日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Adverse Events, Study Completion versus Withdrawal
研究概览
简要总结
ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purpose of this study is to better determine whether ONT01 is safe and tolerated by people with lupus nephritis or SLE. The study also looks at how the administration of ONT01 in combination with widely used treatments given for lupus, including the medication mycophenolate mofetil and others, can improve symptoms of lupus. A total of 61 participants will be enrolled in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years old and able to provide informed consent to participate.
- •Diagnosis of SLE and have fulfilled the ACR classification criteria for SLE during the course of their disease.
- •Active non-renal SLE, with one active non-renal clinical manifestation, who have failed at least 1 disease modifying anti-rheumatic drug (DMARD) therapy (not including hydroxychloroquine and corticosteroids)
- •Active non-renal SLE is defined as having a SLEDAI of 6 or greater (with at least 1 non-renal clinical domain) OR Active nephritis defined as having a no or partial response after initial induction and maintenance therapy with mycophenolate mofetil (and other standard of care therapies) for 3 months or more for class III, IV, IV, V (or combination) nephritis.
- •Active LN is defined as follows: a. kidney biopsy showing Class III, IV, V, III+V, or IV+V, within 1 year from screening, AND b. 24-hour urine protein/creatinine ratio >=1g/g at screening, AND c. absence of partial renal response (PRR)
- •Partial renal response (PRR) is defined as a. 24-hour UPCR improved by >=25% after 3 months from the start of induction standard of care (SOC) therapy (baseline), or >= 50% after 6 months from the induction therapy (UPCR), AND b. 24-hour UPCR<2g/g if baseline was < 3g/g, OR < 3g/g if baseline at induction was >= 3g/g. AND d. EGFR>=60 ml/min/1.73 M2 or no less than 80% of Baseline eGFR (at induction) AND e. No intercurrent rescue therapy, death, or early SOC treatment discontinuation or study withdrawal No response (NR) is defined as a. no achievement of at least a partial renal response, OR b. use of intercurrent rescue therapy, OR c. death
- •Female patients who are women of childbearing potential must agree to use a highly effective form of contraception during the study and for at least 120 days after last exposure to study drug. Male patients with female partners of childbearing potential must use effective barrier contraception (i.e., condoms) during the study and for at least 120 days after last exposure to study drug. Also, patients may not proceed with sperm or egg donation during the study and for at least 120 days after the last exposure to study drug
排除标准
- •Any condition, including any uncontrolled disease (eg, asthma, interstitial lung disease, pulmonary arterial hypertension, morbid obesity), that in the Sponsor-Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct or evaluation.
- •Active central nervous system SLE associated with significant cognitive impairment leading to inability to provide informed consent and/or comply with the protocol.
- •Comorbidities requiring systemic corticosteroid (CS) therapy, such as asthma or inflammatory bowel disease. Systemic is defined as oral, rectal or any injectable route of administration (thus stable dosing by other routes is allowed, including inhaled, topical, ophthalmic, otic, and intranasal).
- •Active clinically significant viral, bacterial or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks of or during the Screening Visit, or completion of oral anti-infectives within 2 weeks before or during the Screening Visit.
- •History of positive human immunodeficiency virus (HIV), hepatitis C antibody and/or polymerase chain reaction, hepatitis B surface antigen (HBsAg) (+), and/or hepatitis B core IgG and/or IgM antibody (+) at the Screening Visit.
- •History, or current diagnosis, of active tuberculosis (TB), or untreated latent TB infection (LTBI), determined by a positive QuantiFERON test at the Screening Visit
- •History of malignancy (hematologic or solid tumor) within 10 years prior to Screening Visit, except adequately treated basal cell or squamous cell carcinomas of the skin (no more than 3 lesions requiring treatment in lifetime) or adequately treated carcinoma in situ/cervical intraepithelial neoplasia of the uterine cervix.
- •Immunization with live or live-attenuated vaccines within 1 month before or during the Screening period.
- •Initiation of, or change in, dosing of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker within 2 weeks before the Screening Visit or during the Screening period.
- •Treatment with Voclosporin or Cyclophosphamide at time of screening.
- •Treatment with other investigational agents within the last 3 months or 5 half-lives, or as per washout requirement from the previous protocol, whichever is longest, prior to the Screening Visit.
- •Clinically significant abnormalities in laboratory tests, unless attributable to active SLE at the Screening Visit
- •Aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase level > 2.5 × upper limit of normal (ULN), or
- •Total bilirubin > 1.5 × ULN, or
- •Hemoglobin < 5.0 mmol/L [9 g/dL], or
- •White blood cells < 2.5 × 109/L, or
- •Absolute neutrophil count < 1500 /mm3, or
- •Platelets < 75 × 109/L
- •Clinically significant chest imaging (e.g. X-ray, computed tomography or magnetic resonance imaging [MRI]) abnormalities per Sponsor-Investigator opinion (e.g. interstitial lung disease) or evidence of active TB on chest X-ray. Chest imaging study must have been performed in 3 months prior to the Screening Visit or during the Screening period.
- •Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
- •Patients are unable or unwilling to adhere to the contraception requirements outlined in inclusion criteria 4.
研究组 & 干预措施
This study will treat patients with Lupus Nephritis (LN) or Systemic Lupus Erythematosus (SLE).
Experimental
Lupus Nephritis
干预措施: ONT01 is a small molecule CD11b modulator. (Drug)
结局指标
主要结局
Adverse Events, Study Completion versus Withdrawal
时间窗: From Enrollment until 18 weeks
This pilot phase 1 study will establish the highest safe dose of ONT01 and help generate preliminary evidence in support of future, large-scale, multi-site, controlled Phase 2 efficacy clinical trials with ONT01 in lupus, so that it can be developed as a novel, myeloid directed, oral therapeutic for lupus.
次要结局
- Effect on SLE and Lupus Nephritis Biomarkers at Day 28(From baseline until Day 28)
研究者
Timothy Niewold
Principal Investigator
Hospital for Special Surgery, New York
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Safety and efficacy of hLF1-11 for the treatment of infectious complications among haematopoietic stem cell transplant recipients. Part B: Clinical Study Protocol SC13: Safety of a 5 mg dose of hLF1-11 given for 10 consecutive days to autologous haematopoietic stem cell transplant recipientsinfecti10035227NL-OMON31209AM-Pharma12
进行中（未招募）
1 期
Anakinra as prevention of mucositis and fever in patients with a stem cell transplantatioMucositis and febrile neutropeniaMedDRA version: 19.0Level: LLTClassification code 10028127Term: MucositisSystem Organ Class: 100000004867MedDRA version: 19.0Level: PTClassification code 10016288Term: Febrile neutropeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-004419-11-NLRadboud university medical center18
已完成
2 期
Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalaand fever during neutropenia)mucositis and febrile neutropenia(inflammation of the lining of the digestive system100188651001796910005908NL-OMON43066Radboud Universitair Medisch Centrum18
终止
1 期
A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaNon Hodgkin LymphomaNCT06622226Ono Pharmaceutical Co., Ltd.2
已完成
1 期
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory CancerSolid TumorAdvanced Solid TumorNCT04659629Neurogene Inc.59